Glen Harbor Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Glen Harbor Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,752	Closed	-$11K	–	1332
2018 Q4	$11K	Sell	4,752 -13,882	-74%	-$122K	﹤0.01%	1263
2018 Q3	$276K	Buy	18,634 +902	+5%	+$14.3K	0.01%	950
2018 Q2	$269K	Buy	17,732 +7,634	+76%	+$130K	0.01%	874
2018 Q1	$190K	Buy	+10,098	New	+$177K	﹤0.01%	984

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glen Harbor Capital Management's SNNA Position: Q1 2019 in Review

Glen Harbor Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2019, closing a stake of 4,752 shares — an estimated $11K sold.

Glen Harbor Capital Management first reported a position in SNNA in Q1 2018 and held it in 4 quarters. The position peaked at $276K in Q3 2018. 57 funds tracked by Wall St. Rank hold SNNA as of Q1 2019.

Glen Harbor Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Glen Harbor Capital Management sold 4,752 Sienna Biopharmaceuticals, Inc. shares in Q1 2019, an estimated $11K.
Glen Harbor Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
Glen Harbor Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $276K in Q3 2018.
57 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2019.

Based on Glen Harbor Capital Management's 13F filing for Q1 2019, filed 13 May 2019.